{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:30:01Z","timestamp":1794673801905,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vaccine.2024.02.010","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:07:50Z","timestamp":1708625270000},"page":"2018-2025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children &lt;2\u00a0years of age"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6436-6859","authenticated-orcid":false,"given":"Sanjeev M.","family":"Bijukchhe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeru","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhishma","family":"Pokhrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2882-1420","authenticated-orcid":false,"given":"Mila","family":"Shakya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikshya","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratistha","family":"Maskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-204X","authenticated-orcid":false,"given":"Himang","family":"Maskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristy","family":"Rajkarkinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabitri","family":"Bista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2342-8531","authenticated-orcid":false,"given":"Yama F.","family":"Mujadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Atherton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5821-1001","authenticated-orcid":false,"given":"Elizabeth","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Mclean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-2512","authenticated-orcid":false,"given":"Matilda","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Theiss","family":"Nyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-8992","authenticated-orcid":false,"given":"Sarah","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O'reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh Prasad","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buddha","family":"Basnyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-719X","authenticated-orcid":false,"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrijana","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.02.010_b0005","unstructured":"IHME. Typhoid fever \u2014 Level 4 cause; 2019. <https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/typhoid-fever-level-4-cause#:\u223c:text=Summary%209%C2%B724%20million%20(95,%E2%80%9313%C2%B79)%20DALYs> [accessed 14th Feb 2023]."},{"key":"10.1016\/j.vaccine.2024.02.010_b0010","unstructured":"Evaluation. EIIfHMa. Global Burden of Disease 2018; 2018. <ghdx.healthdata.org\/gbd-results-tool> [accessed 25\/09 2022]."},{"issue":"6","key":"10.1016\/j.vaccine.2024.02.010_b0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ng.3281","article-title":"Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter-and intracontinental transmission events","volume":"47","author":"Wong","year":"2015","journal-title":"Nat Gene J"},{"issue":"4","key":"10.1016\/j.vaccine.2024.02.010_b0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1473-3099(18)30685-6","article-title":"The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017","volume":"19","author":"Stanaway","year":"2019","journal-title":"Lancet Infect Diseases J"},{"issue":"Supplement_1","key":"10.1016\/j.vaccine.2024.02.010_b0025","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/cid\/ciy846","article-title":"Progress in typhoid fever epidemiology","volume":"68","author":"Crump","year":"2019","journal-title":"Clin Infect Diseases J"},{"issue":"27","key":"10.1016\/j.vaccine.2024.02.010_b0030","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2017.05.001","article-title":"Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low-and middle-income settings","volume":"35","author":"Antill\u00f3n","year":"2017","journal-title":"Vaccine J"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.010_b0035","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1473-3099(18)30804-1","article-title":"Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study","volume":"19","author":"Bilcke","year":"2019","journal-title":"Lancet Infect Diseases J"},{"issue":"suppl_4","key":"10.1016\/j.vaccine.2024.02.010_b0040","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1093\/infdis\/jix598","article-title":"Comparison of strategies and incidence thresholds for Vi conjugate vaccines against typhoid fever: a cost-effectiveness modeling study","volume":"218","author":"Lo","year":"2018","journal-title":"J Infect Diseases J"},{"key":"10.1016\/j.vaccine.2024.02.010_b0045","unstructured":"WHO. Typhoid vaccines: WHO position paper - March 2018; 2018. <https:\/\/www.who.int\/publications\/i\/item\/whio-wer9313> [accessed October 5th 2022]."},{"key":"10.1016\/j.vaccine.2024.02.010_b0050","unstructured":"Gavi. Typhoid conjugate vaccine (TCV) support; 2022. <https:\/\/www.gavi.org\/types-support\/vaccine-support\/typhoid#:\u223c:text=healthy%20market%20dynamics.-,GAVI%20SUPPORT,based%20on%20local%20typhoid%20epidemiology> [accessed 5th March 2023]."},{"key":"10.1016\/j.vaccine.2024.02.010_b0055","unstructured":"WHO. WHO - Prequalification of Typbar-TCV; 2017. <https:\/\/extranet.who.int\/pqweb\/content\/typbar-tcv> [accessed 24\/10 2022]."},{"key":"10.1016\/j.vaccine.2024.02.010_b0060","doi-asserted-by":"crossref","unstructured":"Meiring JE, Gibani M, Basnyat B, et al. The Typhoid Vaccine Acceleration Consortium (TyVAC): vaccine effectiveness study designs: accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26\u201327 October 2016, Oxford, UK. Vaccine J 2017; 35(38): 5081-8.","DOI":"10.1016\/j.vaccine.2017.08.001"},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.010_b0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide\u2013tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Diseases J"},{"issue":"11","key":"10.1016\/j.vaccine.2024.02.010_b0070","doi-asserted-by":"crossref","first-page":"e1561","DOI":"10.1016\/S2214-109X(21)00346-6","article-title":"Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial","volume":"9","author":"Shakya","year":"2021","journal-title":"Lancet Glob Health J"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2024.02.010_b0075","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0264-410X(99)00341-2","article-title":"Vaccination of infants with a four-dose and a three-dose vaccination schedule","volume":"18","author":"Taranger","year":"1999","journal-title":"Vaccine J"},{"issue":"17","key":"10.1016\/j.vaccine.2024.02.010_b0080","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"New England J Med J"},{"issue":"40","key":"10.1016\/j.vaccine.2024.02.010_b0085","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1016\/j.vaccine.2021.08.051","article-title":"Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: a case-control study","volume":"39","author":"Batool","year":"2021","journal-title":"Vaccine J"},{"issue":"7","key":"10.1016\/j.vaccine.2024.02.010_b0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s13312-020-1890-y","article-title":"Immunogenicity and safety of typhoid conjugate vaccine in healthy Indian subjects: a randomized, active-controlled, comparative clinical trial","volume":"57","author":"Kundu","year":"2020","journal-title":"Indian Pediat J"},{"issue":"12","key":"10.1016\/j.vaccine.2024.02.010_b0095","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa2035916","article-title":"Safety and efficacy of a typhoid conjugate vaccine in Malawian children","volume":"385","author":"Patel","year":"2021","journal-title":"New England J Med J"},{"issue":"10301","key":"10.1016\/j.vaccine.2024.02.010_b0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(21)01124-7","article-title":"Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial","volume":"398","author":"Qadri","year":"2021","journal-title":"The Lancet J"},{"issue":"45","key":"10.1016\/j.vaccine.2024.02.010_b0105","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1016\/j.vaccine.2021.07.073","article-title":"Persisting antibody responses to Vi polysaccharide\u2013tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7 years following primary vaccination of children< 2 years of age with, or without, a booster vaccination","volume":"39","author":"Vadrevu","year":"2021","journal-title":"Vaccine J"},{"issue":"36","key":"10.1016\/j.vaccine.2024.02.010_b0110","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1016\/j.vaccine.2022.06.072","article-title":"Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan","volume":"40","author":"Thobani","year":"2022","journal-title":"Vaccine J"},{"issue":"2","key":"10.1016\/j.vaccine.2024.02.010_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol J"},{"issue":"10269","key":"10.1016\/j.vaccine.2024.02.010_b0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2024.02.010_b0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3390\/vaccines9030289","article-title":"Short or long interval between priming and boosting: does it impact on the vaccine immunogenicity?","volume":"9","author":"Pettini","year":"2021","journal-title":"Vaccines J"},{"issue":"11","key":"10.1016\/j.vaccine.2024.02.010_b0130","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1080\/14760584.2019.1688148","article-title":"Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review","volume":"19","author":"Nieto Guevara","year":"2020","journal-title":"Exp Rev Vacc J"},{"key":"10.1016\/j.vaccine.2024.02.010_b0135","unstructured":"l\u2019immunisation INdSPdQCs, Qu\u00e9bec). d. Scientific advisory on the optimal schedule for childhood immunization against pneumococcal disease in Qu\u00e9bec. <https:\/\/www.inspq.qc.ca\/sites\/default\/files\/publications\/2379_opinion_optimal_schedule_childhood_immunization_pneumococcal_disease.pdf> [accessed 25th January 2024]."},{"issue":"5","key":"10.1016\/j.vaccine.2024.02.010_b0140","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.vaccine.2014.12.018","article-title":"Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule","volume":"33","author":"Ladhani","year":"2015","journal-title":"Vaccine J"},{"issue":"2","key":"10.1016\/j.vaccine.2024.02.010_b0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"Typhoid vaccines: WHO position paper, March 2018\u2013recommendations","volume":"37","author":"Organization","year":"2019","journal-title":"Vaccine J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T16:31:24Z","timestamp":1728837084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0264410X24001567"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2\u00a0years of age","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}